Drugs / ERUCOV-VAC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04691947 | Nov 2020 → Nov 2021 | — | Health Institutes of Turkey | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04824391 | Feb 2021 → Mar 2022 | COVID-19 | Health Institutes of Turkey | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ERUCoV-VAC | “two intramuscular doses of ERUCoV-VAC 3 μg or 6 μg (an inactivated vaccine containing alhydrogel as adjuvant) or placebo 21 days apart” PMID 36460536 ↗ Nov 2022 |
| Known as | TURKOVAC | “Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled...” PMID 36460536 ↗ Nov 2022 |
| Modality | Vaccine | “an inactivated whole virion SARS-CoV-2 vaccine” PMID 36460536 ↗ Nov 2022 |
| Route | Intramuscular | “two intramuscular doses of ERUCoV-VAC 3 μg or 6 μg” PMID 36460536 ↗ Nov 2022 |